Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Rhea-AI Summary

Allogene Therapeutics (ALLO) announced the passing of founding board member David Bonderman at age 82. Bonderman, who served as Lead Independent Director since the company's founding in 2018, was instrumental in advancing CAR T-cell therapy development. He was an early supporter of Kite Pharma and later helped establish and guide Allogene's evolution in developing allogeneic CAR T products for cancer and autoimmune disease treatment. His role as a champion of innovation and trusted mentor made significant contributions to the company's development in pioneering AlloCAR T™ products.

News Market Reaction

-5.61%

1 alert

-5.61% News Effect

On the day this news was published, ALLO declined 5.61%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T^™) products for cancer and autoimmune disease, today acknowledged the passing of founding board member, David Bonderman. David died at the age of 82, surrounded by his family.

“We are deeply saddened by the passing of our founding board member and dear friend,” said Arie Belldegrun, M.D., Executive Chairman and Co-Founder of Allogene. “David was more than a board member – he was a champion of innovation, a trusted mentor, and an enduring source of inspiration to all of us. He was also an unwavering believer in the groundbreaking potential of CAR T therapy. Long before Allogene was founded, David recognized the promise of this innovative approach, becoming one of the earliest advocates and supporters of Kite Pharma. His passion and dedication only deepened over time as he helped to guide the establishment and evolution of Allogene. Words cannot express how much he will be missed.”

A steadfast advocate for CAR T-cell therapy, David’s contributions to Allogene are immeasurable. He served on Allogene’s Board of Directors since its founding in 2018, taking on the role of Lead Independent Director. In this capacity, he championed innovation, provided trusted mentorship, and served as a constant source of inspiration to all who worked alongside him.

“David’s contributions to Allogene were immeasurable. His wisdom, guidance, and steadfast commitment to revolutionizing cancer treatment have left an indelible mark on Allogene, the field of CAR T, and the world of science,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. “Our deepest sympathies go out to the Bonderman family and all of those who were fortunate to know him. We join them in honoring a remarkable man whose contributions will continue to save lives and bring transformative treatments to those in need, leaving an enduring legacy in the world of human health.”

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T^™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.

AlloCAR T^™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com

FAQ

Who was David Bonderman and what was his role at Allogene Therapeutics (ALLO)?

David Bonderman was a founding board member of Allogene Therapeutics who served as Lead Independent Director since 2018. He was an early advocate of CAR T therapy and played a important role in the company's establishment and development.

When did Allogene Therapeutics (ALLO) founding board member David Bonderman pass away?

David Bonderman passed away in December 2023 at the age of 82, surrounded by his family.

What is Allogene Therapeutics (ALLO) main focus in product development?

Allogene Therapeutics is a clinical-stage biotechnology company focused on pioneering the development of allogeneic CAR T (AlloCAR T™) products for treating cancer and autoimmune disease.

When was Allogene Therapeutics (ALLO) founded?

Allogene Therapeutics was founded in 2018, with David Bonderman serving as a founding board member and Lead Independent Director.